Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965229154> ?p ?o ?g. }
- W1965229154 endingPage "1713" @default.
- W1965229154 startingPage "1702" @default.
- W1965229154 abstract "Pharmacological inactivation of cancer genes or products is being used as a strategy for therapy in oncology. To investigate the potential role of BCR-ABLp190 cessation in leukaemia development, we generated mice carrying a tetracycline-repressible BCR-ABLp190 transgene. These mice were morphologically normal at birth, and developed leukaemias. Disease was characterized by the presence of B-cell blasts co-expressing myeloid markers, reminiscent of the human counterpart. BCR-ABLp190 activation can initiate leukaemia in both young and adult mice. Transitory expression of BCR-ABLp190 is enough to develop leukaemia. Suppression of the BCR-ABLp190 transgene in leukaemic CombitTA-p190 mice did not rescue the malignant phenotype, indicating that BCR-ABLp190 is not required to maintain the disease in mice. Similar results were obtained by inactivation of BCR-ABLp190 with STI571 (Gleevec; Novartis, East Hanover, NJ, USA) in leukaemic CombitTA-p190 mice. However, gradual suppression of BCR-ABLp190 in leukaemic CombitTA-p190 mice identified a minimum level of BCR-ABLp190 expression necessary to revert the specific block in B-cell differentiation in the leukaemic cells. Overall, the findings indicate that BCR-ABLp190 appears to cause epigenetic and/or genetic changes in tumour-maintaining cells that render them insensitive to BCR-ABLp190 inactivation." @default.
- W1965229154 created "2016-06-24" @default.
- W1965229154 creator A5004744798 @default.
- W1965229154 creator A5009003035 @default.
- W1965229154 creator A5041002773 @default.
- W1965229154 creator A5063205640 @default.
- W1965229154 creator A5073028672 @default.
- W1965229154 creator A5075974674 @default.
- W1965229154 creator A5077566992 @default.
- W1965229154 creator A5080912506 @default.
- W1965229154 creator A5083222784 @default.
- W1965229154 creator A5088409474 @default.
- W1965229154 date "2006-09-18" @default.
- W1965229154 modified "2023-10-01" @default.
- W1965229154 title "Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice" @default.
- W1965229154 cites W1534849470 @default.
- W1965229154 cites W1572020409 @default.
- W1965229154 cites W1729812787 @default.
- W1965229154 cites W1881821787 @default.
- W1965229154 cites W1965553215 @default.
- W1965229154 cites W1972724663 @default.
- W1965229154 cites W1977312224 @default.
- W1965229154 cites W1984976887 @default.
- W1965229154 cites W1987239635 @default.
- W1965229154 cites W1994772304 @default.
- W1965229154 cites W1998919839 @default.
- W1965229154 cites W2008179206 @default.
- W1965229154 cites W2011449061 @default.
- W1965229154 cites W2015616444 @default.
- W1965229154 cites W2016086822 @default.
- W1965229154 cites W2018279800 @default.
- W1965229154 cites W2019616754 @default.
- W1965229154 cites W2020954035 @default.
- W1965229154 cites W2024722383 @default.
- W1965229154 cites W2026654302 @default.
- W1965229154 cites W2033753214 @default.
- W1965229154 cites W2033779669 @default.
- W1965229154 cites W2038588592 @default.
- W1965229154 cites W2039045990 @default.
- W1965229154 cites W2040323778 @default.
- W1965229154 cites W2043011826 @default.
- W1965229154 cites W2062325286 @default.
- W1965229154 cites W2066633769 @default.
- W1965229154 cites W2069501059 @default.
- W1965229154 cites W2069603887 @default.
- W1965229154 cites W2078933765 @default.
- W1965229154 cites W2097384422 @default.
- W1965229154 cites W2107755271 @default.
- W1965229154 cites W2133251648 @default.
- W1965229154 cites W2147124043 @default.
- W1965229154 cites W2147270774 @default.
- W1965229154 cites W2152733951 @default.
- W1965229154 cites W2153701773 @default.
- W1965229154 cites W2207680991 @default.
- W1965229154 cites W2220697339 @default.
- W1965229154 cites W2236985539 @default.
- W1965229154 cites W2300553253 @default.
- W1965229154 cites W2312804644 @default.
- W1965229154 cites W2329648702 @default.
- W1965229154 cites W2413603075 @default.
- W1965229154 cites W34249292 @default.
- W1965229154 cites W85761238 @default.
- W1965229154 doi "https://doi.org/10.1038/sj.onc.1209968" @default.
- W1965229154 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16983340" @default.
- W1965229154 hasPublicationYear "2006" @default.
- W1965229154 type Work @default.
- W1965229154 sameAs 1965229154 @default.
- W1965229154 citedByCount "21" @default.
- W1965229154 countsByYear W19652291542012 @default.
- W1965229154 countsByYear W19652291542014 @default.
- W1965229154 countsByYear W19652291542015 @default.
- W1965229154 countsByYear W19652291542017 @default.
- W1965229154 countsByYear W19652291542018 @default.
- W1965229154 countsByYear W19652291542019 @default.
- W1965229154 countsByYear W19652291542020 @default.
- W1965229154 crossrefType "journal-article" @default.
- W1965229154 hasAuthorship W1965229154A5004744798 @default.
- W1965229154 hasAuthorship W1965229154A5009003035 @default.
- W1965229154 hasAuthorship W1965229154A5041002773 @default.
- W1965229154 hasAuthorship W1965229154A5063205640 @default.
- W1965229154 hasAuthorship W1965229154A5073028672 @default.
- W1965229154 hasAuthorship W1965229154A5075974674 @default.
- W1965229154 hasAuthorship W1965229154A5077566992 @default.
- W1965229154 hasAuthorship W1965229154A5080912506 @default.
- W1965229154 hasAuthorship W1965229154A5083222784 @default.
- W1965229154 hasAuthorship W1965229154A5088409474 @default.
- W1965229154 hasBestOaLocation W19652291541 @default.
- W1965229154 hasConcept C102230213 @default.
- W1965229154 hasConcept C104317684 @default.
- W1965229154 hasConcept C127716648 @default.
- W1965229154 hasConcept C141035611 @default.
- W1965229154 hasConcept C203014093 @default.
- W1965229154 hasConcept C2779282312 @default.
- W1965229154 hasConcept C43907098 @default.
- W1965229154 hasConcept C502942594 @default.
- W1965229154 hasConcept C54355233 @default.
- W1965229154 hasConcept C86803240 @default.
- W1965229154 hasConceptScore W1965229154C102230213 @default.